# Soong-Daystrom Industries, Inc.
## Investor Presentations

**NASDAQ: SDAI**

---

# 2124 Investor Day Presentation
## September 18, 2124 | San Francisco, CA

### Welcome and Strategic Overview
*Dr. Maya Chen, Chief Executive Officer*

---

## Our Mission

**Creating AI that benefits humanity through safe, ethical, and transformative technology.**

For 35 years, Soong-Daystrom Industries has pioneered the development of artificial intelligence and robotics that serve human needs. From companion robots that enrich daily life to industrial automation that makes work safer, from neural interfaces that restore function to AI platforms that power intelligent systems worldwide, our products touch millions of lives every day.

---

## Investment Thesis

### Why Soong-Daystrom?

| Factor | Strength |
|--------|----------|
| **Market Leadership** | #1 in companion robotics, #2 in industrial automation, pioneering neural interfaces |
| **Technology Moat** | Positronic architecture, 340+ patents, unique synthetic consciousness capabilities |
| **Diversified Revenue** | Four complementary segments, B2C and B2B, products and platform |
| **Financial Strength** | 52% gross margin, $6B FCF, fortress balance sheet |
| **Growth Runway** | Multiple $10B+ TAM opportunities, 15%+ organic growth trajectory |
| **R&D Engine** | 18% of revenue, 2,800+ researchers, Project Prometheus breakthrough |

---

## Financial Track Record

### 10-Year Performance (2114-2123)

| Metric | CAGR | FY 2114 | FY 2123 |
|--------|------|---------|---------|
| Revenue | 14.2% | $12.4B | $41.8B |
| Operating Income | 18.7% | $1.1B | $5.6B |
| EPS | 19.4% | $1.08 | $5.78 |
| Free Cash Flow | 17.8% | $0.9B | $5.1B |

### Margin Expansion Story

| Margin | FY 2119 | FY 2121 | FY 2123 | FY 2126E |
|--------|---------|---------|---------|----------|
| Gross | 48.8% | 49.8% | 52.0% | 54-55% |
| Operating | 9.3% | 10.6% | 13.5% | 18-20% |
| Net | 7.7% | 9.0% | 12.7% | 15-17% |

---

## Market Opportunity

### Total Addressable Market by Segment

| Segment | Current TAM | 2128 TAM | SDI Share | Growth Opportunity |
|---------|-------------|----------|-----------|-------------------|
| Consumer Robotics | $48B | $89B | 38% | $34B incremental |
| Industrial Automation | $67B | $142B | 22% | $31B incremental |
| Neural Interfaces | $18B | $67B | 32% | $21B incremental |
| AI Platforms | $34B | $78B | 9% | $7B incremental |
| **Total** | **$167B** | **$376B** | **25%** | **$93B incremental** |

### Key Growth Drivers

1. **Aging Demographics**: 2.1B people over 60 by 2130 driving companion robot demand
2. **Labor Constraints**: Global manufacturing labor shortage of 8M workers by 2127
3. **Healthcare Costs**: Neural interfaces reducing treatment costs by 40-60%
4. **AI Adoption**: Enterprise AI spending growing 28% annually through 2128

---

## Business Segment Deep Dive

### Positronic Companion Series (PCS)
*Sarah Park, Chief Financial Officer*

**Market Position**: #1 globally with 38% market share

**Product Portfolio**:
| Model | Price Point | Target Customer | ASP |
|-------|-------------|-----------------|-----|
| PCS-250 | Entry | First-time buyers | $12,000 |
| PCS-300 | Value | Mainstream consumers | $17,000 |
| PCS-400 | Premium | Quality-focused | $24,000 |
| PCS-500 | Ultra-Premium | High-net-worth, healthcare | $45,000 |

**Growth Strategy**:
1. **Market Expansion**: Entry segment (PCS-250) opens $15B addressable market
2. **Geographic Growth**: Asia-Pacific penetration from 18% to 30% by 2127
3. **Service Revenue**: Growing installed base drives 8-10% annual service growth
4. **PCS v4 Innovation**: Breakthrough natural interaction drives upgrade cycle

**Financial Profile**:
| Metric | FY 2123 | FY 2126E | CAGR |
|--------|---------|----------|------|
| Revenue | $18.2B | $24.0B | 9.6% |
| Op Margin | 18.0% | 21.0% | +300 bps |
| Units | 712K | 1.1M | 15.6% |

---

### Industrial Automation Platform (IAP)
*Marcus Williams, Chief Operating Officer*

**Market Position**: #2 globally with 22% market share

**Competitive Advantages**:
- Proprietary AI-driven task learning reduces deployment time by 60%
- 99.97% uptime reliability, industry-leading
- Seamless integration with existing manufacturing systems
- Comprehensive service and support network

**Customer Base Analysis**:
| Segment | Revenue % | Customers | Growth Rate |
|---------|-----------|-----------|-------------|
| Manufacturing | 40% | 847 | +15% |
| Logistics | 28% | 423 | +28% |
| Mining & Resources | 14% | 156 | +34% |
| Retail | 10% | 289 | +12% |
| Other | 8% | 632 | +8% |

**Project Atlas Opportunity**:
- Heavy industrial robots for mining, construction, heavy manufacturing
- Addressable market: $24B by 2128
- ASP: $1.2M-$3.8M per unit
- Target: $2B revenue by 2127

**Financial Profile**:
| Metric | FY 2123 | FY 2126E | CAGR |
|--------|---------|----------|------|
| Revenue | $14.7B | $22.0B | 14.4% |
| Op Margin | 15.0% | 19.0% | +400 bps |
| Customers | 2,347 | 4,200 | 21.5% |

---

### Neural Interface Modules (NIM)
*Dr. James Okonkwo, Chief Technology Officer*

**Market Position**: Market pioneer with 32% share

**Clinical Portfolio**:
| Indication | Status | TAM | Launch |
|------------|--------|-----|--------|
| Movement Disorders | Approved | $4.2B | 2121 |
| ADHD | Approved | $2.8B | 2123 |
| Chronic Pain | Approved | $3.4B | 2122 |
| Depression | FDA Review | $6.7B | H1 2125 |
| Anxiety | Phase 3 Complete | $4.1B | H2 2125 |
| Cognitive Enhancement | Phase 2 | $12.0B | 2127 |

**Technology Roadmap**:
| Generation | Launch | Key Features | Target Market |
|------------|--------|--------------|---------------|
| NIM-5000 | Current | Surgical implant, full function | Clinical |
| NIM-6000 | 2125 | Minimally invasive, enhanced bandwidth | Medical |
| NIM-7000 | 2127 | Non-invasive, consumer-ready | Consumer |

**Financial Profile**:
| Metric | FY 2123 | FY 2126E | CAGR |
|--------|---------|----------|------|
| Revenue | $5.8B | $12.0B | 27.4% |
| Op Margin | 19.0% | 28.0% | +900 bps |
| Users | 890K | 2.8M | 46.5% |

---

### Synthetic Consciousness Engine (SCE)
*Dr. James Okonkwo, Chief Technology Officer*

**Platform Strategy**: Power the AI ecosystem, not just our products

**Customer Segments**:
| Segment | Revenue % | Use Case | Pricing Model |
|---------|-----------|----------|---------------|
| Enterprise | 60% | Internal AI applications | Annual license |
| OEM | 20% | Embedded in third-party products | Per-unit royalty |
| Developer | 20% | AI application development | Usage-based |

**SCE 4.0 Roadmap**:
- Incorporating Project Prometheus self-referential reasoning
- 2.4x improvement in complex reasoning benchmarks
- Enhanced multi-modal capabilities (text, image, video, sensor)
- Private beta: Q4 2124 | General availability: Q2 2125

**Developer Ecosystem**:
| Metric | FY 2121 | FY 2123 | FY 2126E |
|--------|---------|---------|----------|
| Developers | 62,000 | 124,000 | 280,000 |
| Applications Built | 8,400 | 23,000 | 65,000 |
| API Calls (daily avg) | 12M | 47M | 180M |

**Financial Profile**:
| Metric | FY 2123 | FY 2126E | CAGR |
|--------|---------|----------|------|
| Revenue | $3.1B | $5.5B | 21.0% |
| Op Margin | 34.0% | 42.0% | +800 bps |
| Licenses | 753 | 1,400 | 23.0% |

---

## Research and Innovation
*Dr. James Okonkwo, Chief Technology Officer*

### R&D Investment Philosophy

**Sustained Investment**: Consistently invest 17-19% of revenue in R&D
**Long-term Focus**: Balance near-term product development with breakthrough research
**Safety Priority**: Every major program includes dedicated safety team

### Major Research Programs

**Project Prometheus** ($2.4B total investment)
- **Goal**: True artificial general intelligence with synthetic consciousness
- **Status**: Phase 3 Integration (47% complete)
- **Timeline**: Commercial applications 2126-2027
- **Milestone**: First self-referential AI reasoning demonstrated November 2123
- **Significance**: Potential to transform every SDI product line

**Project Atlas** ($900M total investment)
- **Goal**: Heavy industrial automation for extreme environments
- **Status**: Commercial launch September 2124
- **Pipeline**: $350M+ in committed orders
- **Potential**: $2B+ revenue by 2127

**Project Hermes** ($600M total investment)
- **Goal**: Advanced emotional AI and natural communication
- **Status**: Phase 3 Integration
- **Application**: Integral to PCS v4 and future products
- **Impact**: 34% improvement in user satisfaction in testing

### Intellectual Property Portfolio

| Metric | FY 2119 | FY 2123 | FY 2126E |
|--------|---------|---------|----------|
| Patents Filed (annual) | 89 | 127 | 160 |
| Patents Held | 247 | 340 | 480 |
| Trade Secrets | 89 | 127 | 180 |
| Publications | 34 | 47 | 65 |

---

## Financial Framework
*Sarah Park, Chief Financial Officer*

### Long-Term Financial Targets (FY 2126)

| Metric | FY 2123 | FY 2126 Target | CAGR |
|--------|---------|----------------|------|
| Revenue | $41.8B | $58-62B | 12-14% |
| Gross Margin | 52.0% | 54-55% | +200-300 bps |
| Operating Margin | 13.5% | 18-20% | +450-650 bps |
| EPS | $5.78 | $9.50-10.50 | 18-22% |
| FCF | $5.1B | $8-9B | 16-21% |
| ROIC | 18% | 24-26% | +600-800 bps |

### Revenue Build by Segment (FY 2126E)

| Segment | FY 2123 | FY 2126E | CAGR | % of Total |
|---------|---------|----------|------|------------|
| PCS | $18.2B | $24.0B | 9.6% | 39% |
| IAP | $14.7B | $22.0B | 14.4% | 35% |
| NIM | $5.8B | $12.0B | 27.4% | 19% |
| SCE | $3.1B | $5.5B | 21.0% | 9% |
| **Total** | **$41.8B** | **$63.5B** | **15.0%** | **100%** |

### Operating Leverage Model

**Gross Margin Drivers**:
- Manufacturing automation: +100 bps
- Product mix (NIM growth): +80 bps
- Supply chain optimization: +50 bps
- Pricing power: +20 bps

**OpEx Efficiency**:
- R&D leverage (18% â†’ 17% of revenue): +100 bps
- Sales productivity improvement: +80 bps
- G&A automation: +50 bps
- Scale benefits: +70 bps

---

## Capital Allocation Framework
*Sarah Park, Chief Financial Officer*

### Priorities (in order)

1. **Organic Investment** (50% of FCF)
   - R&D: Maintain 17-19% of revenue investment
   - CapEx: Manufacturing capacity and R&D facilities
   - Working capital: Support growth

2. **Strategic M&A** (15% of FCF average)
   - Tuck-in acquisitions for technology and talent
   - Expand adjacencies (e.g., Quantum Dynamics)
   - Disciplined approach: ROIC > WACC within 3 years

3. **Shareholder Returns** (35% of FCF)
   - Dividends: Stable, growing payout
   - Buybacks: Opportunistic, offsetting dilution

### 3-Year Capital Deployment Plan (2124-2126)

| Use | Amount | % of FCF |
|-----|--------|----------|
| R&D Investment | $25.5B | 40% |
| CapEx | $7.2B | 11% |
| M&A | $6.0B | 10% |
| Dividends | $5.4B | 8% |
| Share Repurchases | $6.0B | 10% |
| Debt Reduction | $2.4B | 4% |
| Cash Accumulation | $11.0B | 17% |
| **Total FCF** | **$63.5B** | **100%** |

### Balance Sheet Strength

| Metric | FY 2123 | FY 2126E |
|--------|---------|----------|
| Cash & Investments | $7.2B | $15.0B |
| Total Debt | $4.5B | $3.0B |
| Net Cash | $2.7B | $12.0B |
| Net Debt/EBITDA | 0.4x | Net Cash |
| Interest Coverage | 34x | 50x+ |

---

## ESG and Corporate Responsibility

### AI Safety Leadership

- **AI Ethics Advisory Board**: 7 external academics, quarterly reviews
- **Safety Investment**: 15% of R&D budget dedicated to safety research
- **Transparency**: Annual AI Safety Report published
- **Regulation**: Proactive engagement with regulators globally

### Environmental Commitment

| Metric | FY 2123 | FY 2026E | Target |
|--------|---------|----------|--------|
| Carbon Emissions (Scope 1+2) | 124K tons | 80K tons | Net zero by 2030 |
| Renewable Energy | 67% | 90% | 100% by 2028 |
| Water Usage | 8.2M gallons | 6.0M gallons | -40% by 2028 |
| Waste Diverted | 78% | 92% | 95% by 2028 |

### Social Impact

- **Education**: $47M annual investment in STEM education
- **Accessibility**: 23 products designed for disability access
- **Workforce Development**: 12,000 hours of community training annually
- **Diversity**: 42% women in leadership (up from 31% in 2119)

---

## Investment Summary

### Bull Case ($420 price target, +35%)

- Project Prometheus enables AGI commercialization by 2026
- NIM consumer launch exceeds expectations
- IAP captures 30%+ market share
- Operating margins reach 22%
- EPS of $12+ by FY 2127

### Base Case ($350 price target, +15%)

- Continued execution on product roadmap
- NIM healthcare adoption continues
- IAP growth of 15%+ sustained
- Operating margins reach 18-20%
- EPS of $10 by FY 2126

### Risk Factors to Monitor

- Project Prometheus execution risk
- Regulatory environment (AI Act, FDA)
- Competitive dynamics
- Macroeconomic sensitivity
- Talent retention

---

## Q&A Session

*Moderated by Michael Torres, VP Investor Relations*

---

# Supplemental Materials

## Detailed Financial Models

### Revenue Bridge FY 2123 to FY 2126

| Driver | Impact |
|--------|--------|
| FY 2123 Base | $41.8B |
| PCS Organic Growth | +$5.8B |
| IAP New Customers | +$4.5B |
| IAP Expansion | +$2.8B |
| NIM Healthcare | +$4.2B |
| NIM Consumer | +$2.0B |
| SCE Platform | +$2.4B |
| **FY 2126E** | **$63.5B** |

### Margin Expansion Drivers

| Factor | Gross Margin Impact | Op Margin Impact |
|--------|---------------------|------------------|
| Volume leverage | +80 bps | +120 bps |
| Product mix (NIM) | +100 bps | +80 bps |
| Manufacturing efficiency | +60 bps | +60 bps |
| R&D leverage | - | +100 bps |
| S&M productivity | - | +80 bps |
| G&A efficiency | - | +60 bps |
| **Total 2123-2026** | **+240 bps** | **+500 bps** |

### Free Cash Flow Build

| Component | FY 2123 | FY 2126E |
|-----------|---------|----------|
| Net Income | $5.3B | $9.5B |
| D&A | $1.2B | $1.8B |
| Stock Comp | $0.8B | $1.2B |
| Working Capital | ($0.2B) | ($0.5B) |
| Other | $0.0B | $0.0B |
| **Operating Cash Flow** | **$7.1B** | **$12.0B** |
| CapEx | ($2.0B) | ($2.8B) |
| **Free Cash Flow** | **$5.1B** | **$9.2B** |
| FCF Margin | 12.2% | 14.5% |
| FCF Conversion | 96% | 97% |

---

## Appendix: Key Metrics Definitions

**Net Revenue Retention**: Revenue from existing customers in current period divided by revenue from those same customers in prior period

**Book-to-Bill**: New orders received divided by revenue recognized in the period

**Average Contract Value**: Total contract value divided by number of contracts

**Customer Satisfaction**: Percentage of customers rating experience 8+ on 10-point scale

**Consciousness Indicator Score**: Proprietary measure of AI self-referential capability (0-1 scale)

---

## Investor Relations Contacts

**Michael Torres**
Vice President, Investor Relations
investor.relations@soong-daystrom.com
+1 (415) 555-7890

**Jennifer Kim**
Director, Investor Relations
jennifer.kim@soong-daystrom.com
+1 (415) 555-7891

**Annual Meeting**: April 24, 2125
**Next Investor Day**: September 2125

---

*This presentation contains forward-looking statements. Actual results may differ materially from those projected. See our SEC filings for risk factors and additional disclosures.*

**Soong-Daystrom Industries, Inc.**
One Soong Plaza
San Francisco, CA 94105
www.soong-daystrom.com
